Kreaxi
  • Our DNA
  • Team
  • Portfolio
  • Impact
  • News
  • Contact
  • Français
Select Page

Theranexus presents an update on the progress of its main programs and announces its cash position as of 31 December 2020. Implemantation of a new equity line.

Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction between neurons and glial cells (the “Company”), presents an update on its activities and...

Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) had granted Orphan Drug Designation (ODD) to AZP-3601, the company’s clinical...

Recent Posts

  • Amolyt Pharma Announces Positive Safety and Efficacy Results from Second Patient Cohort in its Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism
  • Ciliatech presents groundbreaking concept in glaucoma implants, first to bypass opening anterior eye chamber
  • Amolyt Pharma Announces Positive Efficacy and Safety Data from First Cohort of Phase 2a Study of AZP-3601 in Patients with Hypoparathyroidism at the American Society for Bone and Mineral Research 2022 Annual Meeting
  • Amolyt Pharma Announces Two Presentations, Including Phase 2a Data for AZP-3601 in Patients with Hypoparathyroidism, at the American Society for Bone and Mineral Research 2022 Annual Meeting
  • US EPA about to approve Amoéba’s biocide for use in closed cooling systems

Archives

  • October 2022
  • September 2022
  • August 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • May 2021
  • April 2021
  • March 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • July 2020
  • April 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • July 2019
  • March 2019
  • February 2019
  • December 2018
  • November 2018
  • December 2017
  • September 2017
  • April 2017

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

About us

Kreaxi is an investment management firm specialized in the equity financing of innovative, deeptech & lowtech startups with high growth potential. Kreaxi manages regional funds in France, focusing on Auvergne-Rhône-Alpes region as well as French and pan-european funds.

Lyon

101, Chemin Vert
69760 Limonest 
France

+33 4 72 52 39 39

Paris

13-15 rue Taitbout
75009 Paris
France

+33 1 73 02 89 69

  • Twitter
© 2022 Kreaxi. Tous droits réservés. Mentions légales. Informations réglementaires.
Nous utilisons des cookies sur notre site web pour vous offrir l'expérience la plus adaptée en nous souvenant de vos préférences lors de vos prochaines visites. En cliquant sur “Tout accepter”, vous consentez à l'usage de l'ensemble des cookies. Cependant, vous pouvez visiter "Paramétrage" pour détailler votre consentement.
Tout rejeter ParamétrageTout accepter
Manager votre consentement

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
SAVE & ACCEPT